Nymox Pharmaceutical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NYMXF research report →
About the company
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma.
- CEO
- Paul Averback
- IPO
- 1997
- Employees
- 16
- HQ
- Nassau, BS
Price Chart
- Market Cap
- $11.34M
- P/E
- -2.50
- P/S
- 0.00
- P/B
- -1.66
- EV/EBITDA
- -2.64
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 90.31%
- ROIC
- 63.22%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,492,000 · 49.21%
- EPS
- $-0.05 · 50.26%
- Op Income
- $-4,283,000
- FCF YoY
- 35.94%
- 52W High
- $0.20
- 52W Low
- $0.03
- 50D MA
- $0.09
- 200D MA
- $0.07
- Beta
- 8.90
- Avg Volume
- 36.46K
Get TickerSpark's AI analysis on NYMXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NYMXF coverage
Recent articles, reports, and earnings notes.
No research on NYMXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NYMXF report →Similar companies
Peers in the same neighborhood.